Abstract:Abstract PTEN is an important tumor suppressor that plays an essential role in regulating cell proliferation. Loss of PTEN function is implicated in approximately 50% of metastatic cancers. Individuals with pathogenic PTEN variants are at significantly elevated risk of developing hereditary cancer syndromes such as PTEN hamartoma tumor syndrome. While genetic testing for PTEN is valuable for identifying individuals at risk, 47% of 3065 publicly reported PTEN variants are not conclusively classified; they either have conflicting interpretations of pathogenicity or are labeled as “Variants of Uncertain Significance (VUS)” and are not clinically actionable. The lack of a clear interpretation for these PTEN variants hinders the targeted care and surveillance of patients and places a strain on the healthcare system. To overcome this issue, our aim is to develop a clinically relevant tool for assessing the pathogenic effects of PTEN variants.We hypothesize that loss of function (LoF) PTEN variants will lead to changes in cellular phenotypic profiles that can be measured through single-cell phenotypic profiling. Thus, our goal is to investigate the functional status of exogenously expressed PTEN variants in PTEN-/- HEK 293 cells. We developed a multiplexed high content imaging assay to characterize PTEN and its key signaling partners such as phospho-Akt. Additionally, we developed a deep learning based single-cell phenotypic profiling pipeline named Paracell that uses subcellular segmentation to extract 540 phenotypic features. Cells that exhibit abnormal phenotypic profiles are indicative of loss of PTEN function. Preliminary results from testing 73 missense variants of PTEN showed that functional and LoF PTEN variants form distinctive clusters in a two-dimensional UMAP plot based on Paracell outputs, suggesting that our approach can identify potentially pathogenic variants of PTEN.Through characterizing novel VUS, we can elucidate structural domains involved in PTEN’s tumor suppressing activity. The result of these classifications will enable more optimized detection, diagnosis, and surveillance strategies for PTEN-related cancers. Ultimately, we aim to contribute to improving the genetic testing of PTEN and the development of targeted therapies. Citation Format: Ajay P. Singh, Jasmine Wen, David Nguyen, Vedanta Khan, Kiran Dhami, Kaitlynn Meier-Ross, Benjamin Martin, Jesse T. Chao. Characterizing variants of uncertain significance in the tumor suppressor gene known as phosphatase and tensin homolog (PTEN) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6233.

The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers

The Clinical Significance of PTEN Protein Expression in Colorectal Carcinoma

Mutations of PTEN Gene in 117 Chinese Patients with Malignant Melanoma and Their Clinical Significance

The Transcriptomic Landscape of Prostate Cancer Development and Progression: an Integrative Analysis.

PTEN mutations are common in sporadic microsatellite stable colorectal cancer

Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers

Abstract 6233: Characterizing variants of uncertain significance in the tumor suppressor gene known as phosphatase and tensin homolog (PTEN)

The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets

Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis

A retrospective analysis suggests PTEN expression is associated with favorable clinicopathological features of breast cancer

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

Molecular profiling and clinical relevance of low PTEN expression in patients with metastatic hormone-sensitive prostate cancer.

PTEN mutation spectrum in breast cancers and breast hyperplasia

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

Clinical significance of tumor suppressor PTEN in colorectal carcinoma

PTEN gene polymorphisms and susceptibility to oral squamous cell carcinoma in a Chinese Han population

Functions and Regulation of the PTEN Gene in Colorectal Cancer

PTEN Polymorphisms Contribute to Clinical Outcomes of Advanced Lung Adenocarcinoma Patients Treated with Platinum-Based Chemotherapy

PTEN protein loss is associated with an increased risk of recurrence in Chinese patients after prostatectomy for clinically localized prostate cancer

Data from Murine Cell Lines Derived from <i>Pten</i> Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development

The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis